Dirk Jan van Veldhuisen


Dirk Jan van Veldhuisen is Professor of cardiology and has served as Chairman of the department of Cardiology at the University Medical Center Groningen since 2001. He has had his training in Internal Medicine and Cardiology in Rotterdam and Groningen, the Netherlands.

Professor van Veldhuisen has a long-standing interest in Clinical and Experimental Heart Failure. Particular interests are the treatment of heart failure, including both pharmacologic and non-pharmacologic (device) interventions, neurohormonal activation, genetics, arrhythmias, and comorbidities, such as renal dysfunction/anemia .

He is an editorial board member of  of a number of journals and served as national Coordinator/Member of Steering Committee of >35 Heart Failure Trials, and was Principal Investigator of 8 of them.He has served as chairman (1997-2002) and Member of the Working Group of Heart Failure, Netherlands Society of Cardiology and received a large number of Research Grants from the Netherlands Heart Foundation, including the established Investigator grant in 1997.

Professor van Veldhuised is a member of Heart Failure Association of the ESC, and was  a member of the Task Force on the Diagnosis and Treatment of Heart Failure 2008 and the ESC Guidelines Update 2010. He was also a member of the Task Force for the  ESC Guideline on Ventricular Arhythmias and Sudden Cardiac Death in 2015. From 2010-2015, he served as the Editor-in-Chief of European Journal of Heart Failure.He has authrored more that 1000 publications and his Hirsch-index is 116. He has been the promotor of >75 PhD fellows in the last 20 years.

My projects


Pancreatic Exocrine Insufficiency in Heart Failure


Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands: DECISION

Adiposity in Heart Failure with Preserved Ejection Fraction

Epicardial fat can cause heart failure with preserved ejection fraction.


Facilitate personalized therapies in patients with heart failure

Transthyretin amyloidosis cardiomyopathy

My publications

Heart Failure and Pancreas Exocrine Insufficiency: Pathophysiological Mechanisms and Clinical Point of View

view on PubMed

Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients

Sophie L van Veldhuisen, Gijs van Woerden, Martin E W Hemels, Yves G C J America, Rudolf A de Boer, Michiel Rienstra, Dirk J van Veldhuisen, Eric J Hazebroek. Surg Obes Relat Dis 2021.

view on PubMed

Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure with Preserved Ejection Fraction

Thomas M Gorter, Gijs van Woerden, Michiel Rienstra, Michael G Dickinson, Yoran M Hummel, Adriaan A Voors, Elke S Hoendermis, Dirk J van Veldhuisen. JACC Heart Fail 2020.

view on PubMed

Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.

The objective of this study was to assess the association of digoxin with cardiovascular (CV) morbidity and mortality in patients with permanent atrial fibrillation enrolled in the Dutch Rate Control Efficacy in Permanent AF: A Comparison Between Lenient Versus Strict Rate Control II trial as well as to assess the role of digoxin to achieve heart rate targets. The use of digoxin was not associated with increased morbidity and mortality.

view on Heart Rhythm Journal

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

Heart failure with preserved ejection fraction and AF are very common diseases that also often occur in combination, further aggravating each other. Senile amyloidosis, either due to TTR (ATTRwt) or ANP (IAA) appears to play an important role in both diseases and in their interaction. In terms of diagnostics, bone scintigraphy has become available and affords an easy and reliable way to establish the presence of cardiac ATTRwt. Moreover, pharmacological options are now available or under development to treat ATTRwt and possibly also IAA, thereby potentially stopping, or even reversing, the downhill course of some patients with HFpEF and AF.

view on Oxford Academic